1. Molecular Classification of Non–Muscle-Invasive Bladder Cancer (pTa Low-Grade, pT1 Low-Grade, and pT1 High-Grade Subgroups) Using Methylation of Tumor-Suppressor Genes 
Raquel Sacristan, Carolina Gonzalez, Jesus M. Fernández-Gómez, Florentino Fresno, Safwan Escaf, Marta Sánchez-Carbayo 
The Journal of Molecular Diagnostics 
Volume 16, Issue 5, Pages (September 2014)
DOI: /j.jmoldx
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions

2. Figure 1
Methylation of TSGs as a prognostic biomarker of clinical outcome in patients with noninvasive bladder cancer. Survival analysis indicates that the differential methylation for the genes shown significantly predicts recurrence in all patients (A and B) and in the NMI subgroups of pTaLG (C–E), pT1LG (F–I), and pT1HG (J). N, number of cases; O, number of events during follow up. Survival analysis indicates that the differential methylation for several genes significantly predicts recurrence, in the full NMI series PAX5A (P = 0.01) (A); RB1 (P = 0.008) (B); in pTaLG lesions: PAX5A (P = 0.019) (C), WT1 (P = 0.042) (D), and BRCA1 (P = 0.023) (E); in Pt1ALG: PAX6 (P = 0.044) (F), ATM (P = 0.004) (G), CHFR (P = 0.035) (H), and RB1 (P = 0.007) (I); and in pT1HG for PYCARD (P = 0.035) (J).
The Journal of Molecular Diagnostics  , DOI: ( /j.jmoldx )
Copyright © 2014 American Society for Investigative Pathology and the Association for Molecular Pathology Terms and Conditions